Aveanna Healthcare (AVAH) Insider Paul Vigano Sells $8M of Stock

Paul Vigano sold 1,000,000 shares of Aveanna Healthcare Holdings Inc. (AVAH) on June 24, 2026, according to a recent filing with the SEC. The shares were sold at a price of $8.00 each, making the total value of the transaction $8 million. This sale represents a notable shift in ownership for the home healthcare provider.

A Cluster of Insider Sales at Aveanna

The sale by Paul Vigano was not an isolated event. On the same day, June 24, 2026, Robert Williams JR also sold 1,000,000 shares at $8.00 per share, totaling another $8 million. Additionally, LLC J.H. Whitney Equity Partners Vii sold 919,389 shares at that same $8.00 price point, a trade valued at roughly $7.36 million. None of these transactions were conducted under a Rule 10b5-1 trading plan, which is a tool insiders sometimes use to schedule trades in advance. These sales collectively represent a large amount of capital being moved by company insiders on a single day.

Aveanna Healthcare Stock Trends

Shares of Aveanna Healthcare were trading at $8.66 on Saturday. The stock has been navigating a volatile year, with its price fluctuating between a 52-week low of $5.93 and a high of $14.71. At the current price level, the stock is trading just below its 200-day moving average of $8.67 and further below its 50-day moving average of $11.64. With a price-to-earnings (P/E) ratio of 10.67, the company is priced at a level that suggests investors are carefully weighing its earnings potential against its debt levels.

Recent Earnings and Growth

In its most recent financial reporting, Aveanna Healthcare brought in $2.6 billion in revenue, which shows a 13.7% increase compared to previous periods. The company managed a net margin of 10.56% and a return on equity of 1.99%. With earnings per share (EPS) sitting at $1.26, the company has remained profitable while expanding its services. Investors are looking forward to the next earnings announcement, which is expected on November 5, 2026, to see if the company can maintain this growth trajectory.

Analysts Set New Price Targets

Market analysts have been active in updating their views on Aveanna Healthcare. On September 14, 2026, JP Morgan kept a Neutral rating on the stock but raised its price target to $15.00 from a previous $8.00. Barclays also showed confidence on August 28, 2026, maintaining an Overweight rating and lifting its target to $15.00. Other firms like RBC Capital and BMO Capital have assigned Outperform ratings with targets ranging from $14.00 to $16.00. Currently, 10 analysts cover the stock, and the consensus leans toward a buy with an average price target of $14.60.

Home Healthcare Operations

Aveanna Healthcare operates a diverse platform providing pediatric and adult care across the United States. They focus on helping patients stay in their homes rather than high-cost settings like hospitals. Their business is split into three main areas: private duty nursing, home health and hospice care, and medical solutions like nutrition supplies. By keeping patients at home, the company aims to reduce healthcare costs while providing specialized therapy and nursing.

What's Ahead for Aveanna Healthcare Holdings Inc.

The cluster of insider selling on June 24 provides an interesting data point for shareholders to consider alongside the recent analyst price target increases. While these sales happened several months ago, they offer a look at how insiders were positioned during the summer. The upcoming earnings report in November will likely be the next major catalyst for the stock as the market evaluates Aveanna's ability to manage its high debt-to-equity ratio while continuing to grow its home care segments.